Celon Pharma SA (CLN) — Working Capital to Net Assets Ratio
Celon Pharma SA (CLN) has a Working Capital to Net Assets ratio of -0.5% as of March 2026. Working capital of zł-2.44 Million (current assets of zł105.44 Million minus current liabilities of zł107.88 Million) is measured against net assets of zł528.78 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Celon Pharma SA to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Celon Pharma SA Working Capital to Net Assets (2012–2024)
This chart shows how Celon Pharma SA's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of March 2026, the ratio stands at -0.5%, reflecting working capital of zł-2.44 Million against net assets of zł528.78 Million PLN. See CLN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Celon Pharma SA (2012–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Celon Pharma SA from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see CLN stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (PLN) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 16.5% | zł73.30 Million | zł445.21 Million | zł160.43 Million | zł87.12 Million | ▼ -6.7 pp |
| 2023 | 23.2% | zł103.41 Million | zł445.56 Million | zł189.75 Million | zł86.34 Million | ▼ -2.0 pp |
| 2022 | 25.3% | zł121.14 Million | zł479.65 Million | zł237.58 Million | zł116.44 Million | ▼ -9.5 pp |
| 2021 | 34.7% | zł192.34 Million | zł554.00 Million | zł278.70 Million | zł86.36 Million | ▲ +33.6 pp |
| 2020 | 1.1% | zł4.77 Million | zł434.67 Million | zł118.92 Million | zł114.15 Million | ▼ -25.3 pp |
| 2019 | 26.4% | zł117.59 Million | zł445.04 Million | zł143.58 Million | zł25.98 Million | ▼ -16.8 pp |
| 2018 | 43.2% | zł194.03 Million | zł448.73 Million | zł213.75 Million | zł19.72 Million | ▼ -10.3 pp |
| 2017 | 53.6% | zł235.57 Million | zł439.85 Million | zł254.55 Million | zł18.97 Million | ▼ -10.0 pp |
| 2016 | 63.6% | zł255.92 Million | zł402.50 Million | zł270.16 Million | zł14.24 Million | ▲ +55.3 pp |
| 2015 | 8.3% | zł8.39 Million | zł100.82 Million | zł44.95 Million | zł36.55 Million | ▼ -7.1 pp |
| 2014 | 15.4% | zł10.74 Million | zł69.62 Million | zł29.05 Million | zł18.30 Million | ▼ -15.4 pp |
| 2013 | 30.9% | zł16.11 Million | zł52.20 Million | zł26.80 Million | zł10.68 Million | ▲ +24.8 pp |
| 2012 | 6.0% | zł3.35 Million | zł55.57 Million | zł17.57 Million | zł14.22 Million | — |